Achieve Life Sciences Q2 FY26 net loss widens to $74.77 million

Reuters2026/08/11 12:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Achieve Life Sciences posted a GAAP net loss of USD 74.77 million for Q2 2026, widening from USD 12.72 million a year earlier.
GAAP operating expenses rose to USD 18.39 million from USD 12.56 million; the loss included a USD 48.7 million non-cash warrant liability charge.
Cash, cash equivalents and marketable securities climbed to USD 187.3 million at June 30, 2026, from USD 36.4 million at Dec. 31, 2025.
FDA issued a Complete Response Letter on cytisinicline tied to cGMP observations at a prior third-party manufacturer; no efficacy or clinical safety deficiencies were cited.
Finished drug product manufacturing is shifting to Adare Pharma Solutions; NDA resubmission is targeted for Q4 2026 with potential FDA approval in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Achieve Life Sciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110830PRIMZONEFULLFEED9807502) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Achieve Life Sciences Q2 FY26 net loss widens to $74.77 million

You may also like

Crypto prices